vs
Apellis Pharmaceuticals, Inc.（APLS）与STANDEX INTERNATIONAL CORP（SXI）财务数据对比。点击上方公司名可切换其他公司
STANDEX INTERNATIONAL CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$221.3M vs $199.9M），STANDEX INTERNATIONAL CORP净利率更高（1.0% vs -29.5%，领先30.4%），STANDEX INTERNATIONAL CORP同比增速更快（16.6% vs -5.9%），STANDEX INTERNATIONAL CORP自由现金流更多（$12.9M vs $-14.3M），过去两年STANDEX INTERNATIONAL CORP的营收复合增速更高（11.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Stanex International是一家多元化跨国制造企业，业务覆盖电子、雕刻、科学仪器、工程技术及特种解决方案五大板块，在美、欧、加、日、新、墨、土、印、中多地设有运营主体，全球共设12个业务单元及5个汇报板块，旗下拥有Bakers Pride等多个子品牌。
APLS vs SXI — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $221.3M |
| 净利润 | $-59.0M | $2.1M |
| 毛利率 | — | 41.7% |
| 营业利润率 | -25.6% | 16.1% |
| 净利率 | -29.5% | 1.0% |
| 营收同比 | -5.9% | 16.6% |
| 净利润同比 | -62.2% | 147.4% |
| 每股收益（稀释后） | $-0.40 | $0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $221.3M | ||
| Q3 25 | $458.6M | $217.4M | ||
| Q2 25 | $178.5M | $222.0M | ||
| Q1 25 | $166.8M | $207.8M | ||
| Q4 24 | $212.5M | $189.8M | ||
| Q3 24 | $196.8M | $170.5M | ||
| Q2 24 | $199.7M | $180.2M | ||
| Q1 24 | $172.3M | $177.3M |
| Q4 25 | $-59.0M | $2.1M | ||
| Q3 25 | $215.7M | $15.1M | ||
| Q2 25 | $-42.2M | $14.8M | ||
| Q1 25 | $-92.2M | $21.9M | ||
| Q4 24 | $-36.4M | $857.0K | ||
| Q3 24 | $-57.4M | $18.2M | ||
| Q2 24 | $-37.7M | $19.6M | ||
| Q1 24 | $-66.4M | $15.8M |
| Q4 25 | — | 41.7% | ||
| Q3 25 | — | 41.6% | ||
| Q2 25 | — | 41.1% | ||
| Q1 25 | — | 39.7% | ||
| Q4 24 | — | 37.6% | ||
| Q3 24 | — | 41.1% | ||
| Q2 24 | — | 38.5% | ||
| Q1 24 | — | 38.5% |
| Q4 25 | -25.6% | 16.1% | ||
| Q3 25 | 48.7% | 13.6% | ||
| Q2 25 | -18.6% | 15.6% | ||
| Q1 25 | -50.0% | 12.6% | ||
| Q4 24 | -12.3% | 4.5% | ||
| Q3 24 | -24.0% | 14.1% | ||
| Q2 24 | -14.7% | 15.1% | ||
| Q1 24 | -36.0% | 12.3% |
| Q4 25 | -29.5% | 1.0% | ||
| Q3 25 | 47.0% | 6.9% | ||
| Q2 25 | -23.6% | 6.7% | ||
| Q1 25 | -55.3% | 10.5% | ||
| Q4 24 | -17.1% | 0.5% | ||
| Q3 24 | -29.2% | 10.7% | ||
| Q2 24 | -18.9% | 10.9% | ||
| Q1 24 | -38.5% | 8.9% |
| Q4 25 | $-0.40 | $0.17 | ||
| Q3 25 | $1.67 | $1.25 | ||
| Q2 25 | $-0.33 | $1.23 | ||
| Q1 25 | $-0.74 | $1.81 | ||
| Q4 24 | $-0.30 | $0.07 | ||
| Q3 24 | $-0.46 | $1.53 | ||
| Q2 24 | $-0.30 | $1.64 | ||
| Q1 24 | $-0.54 | $1.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $97.0M |
| 总债务越低越好 | — | $534.7M |
| 股东权益账面价值 | $370.1M | $700.2M |
| 总资产 | $1.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.76× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $97.0M | ||
| Q3 25 | $479.2M | $98.7M | ||
| Q2 25 | $370.0M | $104.5M | ||
| Q1 25 | $358.4M | $109.8M | ||
| Q4 24 | $411.3M | $121.1M | ||
| Q3 24 | $396.9M | $164.6M | ||
| Q2 24 | $360.1M | $154.2M | ||
| Q1 24 | $325.9M | $138.8M |
| Q4 25 | — | $534.7M | ||
| Q3 25 | — | $544.6M | ||
| Q2 25 | — | $552.5M | ||
| Q1 25 | — | $579.4M | ||
| Q4 24 | — | $534.3M | ||
| Q3 24 | — | $149.0M | ||
| Q2 24 | — | $148.9M | ||
| Q1 24 | $93.1M | $148.8M |
| Q4 25 | $370.1M | $700.2M | ||
| Q3 25 | $401.2M | $707.7M | ||
| Q2 25 | $156.3M | $711.7M | ||
| Q1 25 | $164.2M | $686.9M | ||
| Q4 24 | $228.5M | $656.0M | ||
| Q3 24 | $237.1M | $658.0M | ||
| Q2 24 | $264.3M | $621.5M | ||
| Q1 24 | $266.7M | $619.0M |
| Q4 25 | $1.1B | $1.6B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.5B | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | $993.5M |
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.78× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 0.81× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | 0.35× | 0.24× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $20.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $12.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 5.8% |
| 资本支出强度资本支出/营收 | 0.1% | 3.5% |
| 现金转化率经营现金流/净利润 | — | 9.70× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $51.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $20.6M | ||
| Q3 25 | $108.5M | $16.8M | ||
| Q2 25 | $4.4M | $33.4M | ||
| Q1 25 | $-53.4M | $9.5M | ||
| Q4 24 | $19.4M | $9.1M | ||
| Q3 24 | $34.1M | $17.6M | ||
| Q2 24 | $-8.3M | $28.5M | ||
| Q1 24 | $-133.0M | $24.4M |
| Q4 25 | $-14.3M | $12.9M | ||
| Q3 25 | $108.3M | $10.4M | ||
| Q2 25 | $4.4M | $24.8M | ||
| Q1 25 | $-53.4M | $3.5M | ||
| Q4 24 | $19.3M | $2.1M | ||
| Q3 24 | — | $10.8M | ||
| Q2 24 | $-8.4M | $22.0M | ||
| Q1 24 | $-133.3M | $19.2M |
| Q4 25 | -7.1% | 5.8% | ||
| Q3 25 | 23.6% | 4.8% | ||
| Q2 25 | 2.5% | 11.2% | ||
| Q1 25 | -32.0% | 1.7% | ||
| Q4 24 | 9.1% | 1.1% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | -4.2% | 12.2% | ||
| Q1 24 | -77.3% | 10.8% |
| Q4 25 | 0.1% | 3.5% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 3.9% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.0% | 3.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.0% | 3.6% | ||
| Q1 24 | 0.2% | 2.9% |
| Q4 25 | — | 9.70× | ||
| Q3 25 | 0.50× | 1.12× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | — | 0.44× | ||
| Q4 24 | — | 10.57× | ||
| Q3 24 | — | 0.97× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SXI
| Electronics Products Group | $115.7M | 52% |
| Engraving Services | $33.0M | 15% |
| Engineering Technologies Components | $30.6M | 14% |
| Transferred Over Time | $21.2M | 10% |
| Hydraulics Cylinders And System | $11.4M | 5% |
| Merchandising Display | $8.4M | 4% |
| Engraving Products | $2.7M | 1% |
